Harrow Reports Q1 Revenue Decline & Wider Loss, Reaffirms Full-Year Guidance on Strong Product Demand
HROW sits 71% above its 52-week low of $21.12 on elevated volume (1.9× avg).
Summary
Harrow reported a Q1 2026 revenue decline and wider net loss, attributing the shortfall to temporary factors, while reaffirming its full-year 2026 financial guidance based on strong underlying product demand and an expanded sales force.
Key Events · Earnings and Guidance · HROW
-
Q1 2026 Financial Results
Reported total revenues of $44.2 million, an 8% decrease year-over-year, and a net loss of $(27.6) million, significantly wider than the prior year's $(17.8) million.
-
Full-Year Guidance Reaffirmed
Reaffirmed 2026 revenue guidance of $350 million to $365 million and Adjusted EBITDA of $80 million to $100 million, with Q2 revenue expected between $71 million and $81 million.
-
VEVYE Performance & Adjustment
VEVYE revenue was $20.9 million, impacted by an approximate $8 million non-recurring gross-to-net adjustment related to new commercial coverage, which has since been recalibrated. Underlying demand for VEVYE showed record prescription performance.
-
Product Portfolio Updates
IHEEZO unit demand increased 18% year-over-year, and TRIESENCE unit demand more than doubled. The company also highlighted the upcoming BYOOVIZ launch in Q3 2026 and the IOPIDINE 1% J-Code effective July 1, 2026.
Analysis · HROW · Life Sciences
This 8-K reports Harrow's Q1 2026 financial results, which showed a year-over-year decline in revenue and a wider net loss. However, the company attributes the revenue shortfall to a temporary, non-recurring gross-to-net adjustment for VEVYE and channel inventory dynamics for IHEEZO, which are now resolved. Crucially, management reaffirmed its full-year 2026 revenue and Adjusted EBITDA guidance, signaling confidence in a strong rebound in the latter half of the year driven by accelerating demand for key products, a recently expanded sales force, and upcoming product launches and reimbursement changes. Investors will be watching for evidence of this anticipated acceleration in Q2 and beyond to validate the full-year outlook.
How filings like this one have moved
In the 30 days to Oct 4, 2026, 29.1% of the 1568 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.60%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HROW was trading at $36.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $21.12 to $54.85. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.